Cargando…
Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
Resistance of rhabdomyosarcoma to current therapies remains one of the key issues in pediatric oncology. Since the success of most cytotoxic therapies in the treatment of cancer, for example, chemotherapy, depends on intact signaling pathways that mediate programmed cell death (apoptosis), defects i...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263644/ https://www.ncbi.nlm.nih.gov/pubmed/22294874 http://dx.doi.org/10.1155/2012/326210 |
_version_ | 1782221902615412736 |
---|---|
author | Fulda, Simone |
author_facet | Fulda, Simone |
author_sort | Fulda, Simone |
collection | PubMed |
description | Resistance of rhabdomyosarcoma to current therapies remains one of the key issues in pediatric oncology. Since the success of most cytotoxic therapies in the treatment of cancer, for example, chemotherapy, depends on intact signaling pathways that mediate programmed cell death (apoptosis), defects in apoptosis programs in cancer cells may result in resistance. Evasion of apoptosis in rhabdomyosarcoma may be caused by defects in the expression or function of critical mediators of apoptosis or in aberrant expression of antiapoptotic proteins. Therefore, the identification of the molecular mechanisms that confer primary or acquired resistance to apoptosis in rhabdomyosarcoma presents a critical step for the rational development of molecular targeted drugs. This approach will likely open novel perspectives for the treatment of rhabdomyosarcoma. |
format | Online Article Text |
id | pubmed-3263644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-32636442012-01-31 Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma Fulda, Simone Sarcoma Review Article Resistance of rhabdomyosarcoma to current therapies remains one of the key issues in pediatric oncology. Since the success of most cytotoxic therapies in the treatment of cancer, for example, chemotherapy, depends on intact signaling pathways that mediate programmed cell death (apoptosis), defects in apoptosis programs in cancer cells may result in resistance. Evasion of apoptosis in rhabdomyosarcoma may be caused by defects in the expression or function of critical mediators of apoptosis or in aberrant expression of antiapoptotic proteins. Therefore, the identification of the molecular mechanisms that confer primary or acquired resistance to apoptosis in rhabdomyosarcoma presents a critical step for the rational development of molecular targeted drugs. This approach will likely open novel perspectives for the treatment of rhabdomyosarcoma. Hindawi Publishing Corporation 2012 2012-01-12 /pmc/articles/PMC3263644/ /pubmed/22294874 http://dx.doi.org/10.1155/2012/326210 Text en Copyright © 2012 Simone Fulda. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Fulda, Simone Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma |
title | Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma |
title_full | Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma |
title_fullStr | Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma |
title_full_unstemmed | Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma |
title_short | Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma |
title_sort | cell death pathways as therapeutic targets in rhabdomyosarcoma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263644/ https://www.ncbi.nlm.nih.gov/pubmed/22294874 http://dx.doi.org/10.1155/2012/326210 |
work_keys_str_mv | AT fuldasimone celldeathpathwaysastherapeutictargetsinrhabdomyosarcoma |